Seelos announces FDA acceptance of IND application for SLS-005 for Sanfilippo Syndrome

This article was originally published here

The FDA has advised Seelos that it may proceed with the proposed clinical trial SLS-005-201 for Mucopolysaccharidosis type III (Sanfilippo syndrome). “We are very pleased to have received

The post Seelos announces FDA acceptance of IND application for SLS-005 for Sanfilippo Syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply